

**ASX RELEASE**

**25<sup>th</sup> Sep 2023**

**New Chief Financial Officer Mr Tim Luscombe**

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce that Mr Tim Luscombe will replace Mr Hamish George as Chief Financial Officer (CFO) of the Company.

Mr Luscombe is a highly experienced Chartered Accountant who holds a Bachelor of Commerce from the University of Melbourne and a Certificate in Governance Practice from the Governance Institute of Australia. He is a Director at Bio101 Financial Advisory and has been working with Amplia in a senior accounting capacity over the last two years.

Amplia’s CEO and Managing Director, Dr Chris Burns, commented: “We are delighted that Tim is taking on the role of CFO at Amplia. His knowledge of the Company and close working relationship with the team means it will be a seamless transition. We would also like to thank Hamish for his excellent work over the previous years.”

Mr Luscombe commented: “I am thrilled to take on the role of CFO and continue to work with the Company as it grows and progresses its exciting clinical programs.”

This ASX announcement is authorised for release by the Board.

**Investor Contact:**

Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)

**Media Contact:**

HACK Director, Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit [www.ampliatx.com](http://www.ampliatx.com) and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx), [Threads](https://www.threads.net/@ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/amplia-therapeutics).